Need help finding what you are looking for?
Contact Us
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1388197
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1388197
Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents); By Disease Condition; By Region; Segment Forecast, 2023 - 2032
PUBLISHED:
PAGES: 118 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global gout therapeutics market size is expected to reach USD 6.04 billion by 2032, according to a new study by Polaris market research. The report "Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents); By Disease Condition; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Biologics has a rising acceptance and increased research and development focused on regeneration therapies. These innovative treatment approaches show great promise in addressing gout's symptoms and underlying causes. Additionally, there have been significant advancements in imaging modalities, which have enhanced the ability to diagnose and monitor gout effectively.
Furthermore, a greater understanding of the disease and its risk factors leads to increased awareness among healthcare professionals and patients. Gout primarily affects men over 40 with high uric acid levels in their blood. Males are more susceptible to developing gout compared to females. Excessive uric acid leads to the formation of needle-like crystals, which can result in joint pain, inflammation, and soreness.
These combined factors have propelled the demand for effective gout therapeutics. Pharmaceutical companies and researchers are actively working to develop new and improved treatment options to address the symptoms and long-term management of gout. The aim is to provide patients with targeted therapies that alleviate pain, reduce inflammation, and prevent recurrent gout attacks.
Gout is growing globally due to lifestyle changes and dietary factors, expanding the patient pool. The market is witnessing advancements in treatment options, including new drug formulations and combinations, offering improved efficacy and convenience.
Additionally, personalized medicine approaches are gaining traction, tailoring treatments based on individual patient characteristics. Rising awareness and diagnosis rates, technological advancements, and expansion in emerging markets further contribute to the market's growth. Collaborations and partnerships among key industry players also facilitate research and development efforts in gout therapeutics.
Gout Therapeutics Market Report Highlights
NSAIDs segment dominated the market with highest share. Due to their widespread availability, cost-effectiveness, and efficacy during severe gout attacks, NSAIDs are the preferred first-line treatment for reducing inflammation and pain in rheumatic and non-rheumatic diseases.
Chronic segment anticipated to hold the largest revenue share of the market. The growth of this segment is fueled by the introduction of various urate-lowering drugs and the potential for new treatments to enter the market.
North America dominated the market and willing to maintain its dominance over the forecast period. Gout affects many people in North America, with an estimated 8.3 million individuals affected in the United States alone and a prevalence rate ranging from 1% to 4%.
The global key market players include: Ablynx, Antares Pharma, CymaBay Therapeutics, Astellas Pharma, AstraZeneca, Horizon Pharma, Boehringer Ingelheim, Merck, Eisai, Regeneron Pharmaceuticals, Eli Lilly and others.
Polaris market research has segmented the gout therapeutics market report based on drug class, disease condition, and region:
Gout Therapeutics, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)
- Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Urate Lowering Agents
Gout Therapeutics, Disease Condition Outlook (Revenue - USD Billion, 2019 - 2032)
- Acute
- Chronic
Gout Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Product Code: PM1611
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Gout Therapeutics Market Insights
- 4.1. Gout Therapeutics Market - Industry Snapshot
- 4.2. Gout Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing prevalence of gout worldwide
- 4.2.1.2. Continuous research and development activities
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Cost of treatment
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Gout Therapeutics Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Gout Therapeutics Market, by Drug Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Gout Therapeutics, by Drug Class, 2019-2032 (USD Billion)
- 5.3. Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
- 5.3.1. Global Gout Therapeutics Market, by Non-steroidal Anti-Inflammatory Drugs (NSAIDs) by Region, 2019-2032 (USD Billion)
- 5.4. Corticosteroids
- 5.4.1. Global Gout Therapeutics Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
- 5.5. Colchicine
- 5.5.1. Global Gout Therapeutics Market, by Colchicine, by Region, 2019-2032 (USD Billion)
- 5.6. Urate Lowering Agents
- 5.6.1. Global Gout Therapeutics Market, by Urate Lowering Agents, by Region, 2019-2032 (USD Billion)
6. Global Gout Therapeutics Market, by Disease Condition
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 6.3. Acute
- 6.3.1. Global Gout Therapeutics Market, by Acute, by Region, 2019-2032 (USD Billion)
- 6.4. Chronic
- 6.4.1. Global Gout Therapeutics Market, by Chronic, by Region, 2019-2032 (USD Billion)
7. Global Gout Therapeutics Market, by Geography
- 7.1. Key findings
- 7.2. Introduction
- 7.2.1. Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
- 7.3. Gout Therapeutics Market - North America
- 7.3.1. North America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.3.2. North America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.3.3. Gout Therapeutics Market - U.S.
- 7.3.3.1. U.S.: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.3.3.2. U.S.: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.3.4. Gout Therapeutics Market - Canada
- 7.3.4.1. Canada: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.3.4.2. Canada: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4. Gout Therapeutics Market - Europe
- 7.4.1. Europe: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.2. Europe: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.3. Gout Therapeutics Market - UK
- 7.4.3.1. UK: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.3.2. UK: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.4. Gout Therapeutics Market - France
- 7.4.4.1. France: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.4.2. France: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.5. Gout Therapeutics Market - Germany
- 7.4.5.1. Germany: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.5.2. Germany: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.6. Gout Therapeutics Market - Italy
- 7.4.6.1. Italy: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.6.2. Italy: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.7. Gout Therapeutics Market - Spain
- 7.4.7.1. Spain: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.7.2. Spain: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.8. Gout Therapeutics Market - Netherlands
- 7.4.8.1. Netherlands: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.8.2. Netherlands: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.9. Gout Therapeutics Market - Russia
- 7.4.9.1. Russia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.9.2. Russia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5. Gout Therapeutics Market - Asia Pacific
- 7.5.1. Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.2. Asia Pacific: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.3. Gout Therapeutics Market - China
- 7.5.3.1. China: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.3.2. China: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.4. Gout Therapeutics Market - India
- 7.5.4.1. India: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.4.2. India: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.5. Gout Therapeutics Market - Malaysia
- 7.5.5.1. Malaysia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.5.2. Malaysia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.6. Gout Therapeutics Market - Japan
- 7.5.6.1. Japan: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.6.2. Japan: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.7. Gout Therapeutics Market - Indonesia
- 7.5.7.1. Indonesia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.7.2. Indonesia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.8. Gout Therapeutics Market - South Korea
- 7.5.8.1. South Korea: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.8.2. South Korea: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6. Gout Therapeutics Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.2. Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.3. Gout Therapeutics Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.3.2. Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.4. Gout Therapeutics Market - UAE
- 7.6.4.1. UAE: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.4.2. UAE: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.5. Gout Therapeutics Market - Israel
- 7.6.5.1. Israel: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.5.2. Israel: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.6. Gout Therapeutics Market - South Africa
- 7.6.6.1. South Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.6.2. South Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7. Gout Therapeutics Market - Latin America
- 7.7.1. Latin America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.7.2. Latin America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.3. Gout Therapeutics Market - Mexico
- 7.7.3.1. Mexico: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.7.3.2. Mexico: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.4. Gout Therapeutics Market - Brazil
- 7.7.4.1. Brazil: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.7.4.2. Brazil: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.5. Gout Therapeutics Market - Argentina
- 7.7.5.1. Argentina: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.7.5.2. Argentina: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Ablynx
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Antares Pharma
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Astellas Pharma
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. AstraZeneca
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Boehringer Ingelheim
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. CymaBay Therapeutics
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Eisai
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Eli Lilly
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. GlaxoSmithKline
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Horizon Pharma
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. JW Pharmaceutical
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
- 9.12. LG Life Sciences
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
- 9.13. Merck
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
- 9.14. Novartis
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
- 9.15. Novo Nordisk
- 9.15.1. Company Overview
- 9.15.2. Financial Performance
- 9.15.3. Product Benchmarking
- 9.15.4. Recent Development
- 9.16. Regeneron Pharmaceuticals
- 9.16.1. Company Overview
- 9.16.2. Financial Performance
- 9.16.3. Product Benchmarking
- 9.16.4. Recent Development
- 9.17. Sandoz (a subsidiary of Novartis)
- 9.17.1. Company Overview
- 9.17.2. Financial Performance
- 9.17.3. Product Benchmarking
- 9.17.4. Recent Development
- 9.18. Sanofi
- 9.18.1. Company Overview
- 9.18.2. Financial Performance
- 9.18.3. Product Benchmarking
- 9.18.4. Recent Development
- 9.19. Takeda Pharmaceuticals
- 9.19.1. Company Overview
- 9.19.2. Financial Performance
- 9.19.3. Product Benchmarking
- 9.19.4. Recent Development
- 9.20. Teijin Pharma
- 9.20.1. Company Overview
- 9.20.2. Financial Performance
- 9.20.3. Product Benchmarking
- 9.20.4. Recent Development
- 9.21. Vertex Pharmaceuticals
- 9.21.1. Company Overview
- 9.21.2. Financial Performance
- 9.21.3. Product Benchmarking
- 9.21.4. Recent Development
Product Code: PM1611
List of Tables
- Table 1 Global Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 2 Global Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 3 Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
- Table 4 North America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 5 North America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 6 U.S.: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 7 U.S.: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 8 Canada: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 9 Canada: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 10 Europe: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 11 Europe: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 12 UK: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 13 UK: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 14 France: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 15 France: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 16 Germany: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 17 Germany: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 18 Italy: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 19 Italy: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 20 Spain: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 21 Spain: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 22 Netherlands: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 23 Netherlands: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 24 Russia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 25 Russia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 26 Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 27 Asia Pacific: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 28 China: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 29 China: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 30 India: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 31 India: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 32 Malaysia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 33 Malaysia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 34 Japan: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 35 Japan: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 36 Indonesia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 37 Indonesia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 38 South Korea: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 39 South Korea: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 40 Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 41 Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 42 Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 43 Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 44 UAE: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 45 UAE: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 46 Israel: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 47 Israel: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 48 South Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 49 South Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 50 Latin America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 51 Latin America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 52 Mexico: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 53 Mexico: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 54 Brazil: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 55 Brazil: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- Table 56 Argentina: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- Table 57 Argentina: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
List of Figures
- Figure 1 Global Gout Therapeutics Market, 2019-2032 (USD Billion)
- Figure 2 Integrated Ecosystem
- Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
- Figure 4 Market by Geography
- Figure 5 Porter's Five Forces
- Figure 6 Market by Disease Condition
- Figure 7 Global Gout Therapeutics Market, by Disease Condition, 2022 & 2032 (USD Billion)
- Figure 8 Market by Drug Class
- Figure 9 Global Gout Therapeutics Market, by Drug Class, 2022 & 2032 (USD Billion)
- Figure 10 Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
- Figure 11 Strategic Analysis - Gout Therapeutics Market
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.